Stockreport

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara, Inc.  (SVRA) 
Last savara, inc. earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: savarapharma.com/investors/events-presentations
PDF -- EMA Review of MOLBREEVI MAA Has Now Initiated, Decision Expected in Q1 2027 ---- MOLBREEVI Biologics License Application (BLA) is Currently Under Priority Review with [Read more]